Bristol Myers Squibb (BMS) is making significant strides in reshaping its pharmaceutical commercialization strategy, specifically by leveraging artificial intelligence (AI) to enhance efficiency and speed. This news is particularly pertinent as the US biopharma giant gears up for what it defines as one of its most active pipeline phases, especially within the burgeoning Indian market. With expectations of numerous global data readouts across various therapeutic categories, including oncology, haematology, cardiovascular health, and immunology within the next 12 to 18 months, the company is strategically positioning itself in India as a key growth engine.

Having earned over $48 billion in sales last year, BMS is not just marking its presence but also scaling up with the introduction of innovative drugs for various medical conditions. Notable launches in the pipeline include mavacamten (Camzyos) for hypertrophic cardiomyopathy, as well as treatments for multiple myeloma and cardiovascular illnesses. The focus on AI commercialization is aimed at cutting down drug launch timelines significantly and enhancing overall patient engagement through personalized communication strategies.

Adam Lenkowsky, the executive vice president and chief commercialization officer at BMS, emphasizes that the time is ripe for the company, particularly as India serves as an exciting and rapidly growing market. The swift growth achieved by BMS in oncology and other areas reinforces the need for now rolling out an expanded product portfolio to meet the needs of more patients.

Investing more than $100 million into AI-driven commercialization, BMS’s recently established Gen AI hub in partnership with Accenture in Mumbai is a cornerstone of this innovative approach. The hub aims to drastically reduce the timeline required to communicate new clinical trial data from as long as six months to just two weeks, thus ensuring healthcare professionals are updated in real-time.

This improvement in communication not only fosters quicker adoption of new medicines but also enables an actionable understanding of how physicians engage with the materials provided. Traditionally, it would take BMS six to twelve months to gauge this engagement, which they now anticipate will accelerate significantly, facilitating a more efficient commercial strategy moving forward.

Interestingly, BMS is keen to assert that India’s role in this ambitious plan is not merely as a low-cost backend office. Anvita Karara, head of AI commercial transformation at BMS, has declared that the Mumbai team is at the forefront of AI innovation. This commitment to innovative practices is expected to redefine operational methodologies across the organization.

With plans to augment the workforce at the Mumbai hub, BMS is not only bolstering its employee base but is also keen on harnessing technological advancements to drive innovation. Currently, the AI hub will employ 250 technologists, a number that BMS intends to increase to further support its growth initiatives.

The emphasis on AI is also critical for BMS as it prepares for potential patent expirations of its blockbuster drugs. By employing sophisticated AI technologies, the company aims to safeguard its market position and continue delivering cutting-edge medical solutions in India and beyond.

In conclusion, Bristol Myers Squibb’s strategic investment in AI and its multifaceted drug development initiatives showcase a pivotal shift towards innovation-centric operations. By integrating novel technologies and fostering a dynamic commercial environment in India, BMS is not just enhancing its own growth trajectory but also significantly impacting patient care through faster access to advanced therapies.